

August 3, 2023
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Revision to Earnings Forecast for FY 2023

TOKYO, Japan, August 3, 2023 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio" or the "Company") today announced that the Company's Board of Directors today approved the following revision to the earnings forecast for fiscal year ending December 31, 2023. The earnings forecast was previously announced on February 9, 2023. The revision reflects the Company's current performance trends and outlook.

1. Revision to Earnings Forecast for FY 2023 (January 1, 2023 to December 31, 2023)

	Net Sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Previous Forecast (A)	7,000	△331	△351	△370	△9.48
Revised Forecast (B)	6,477	△331	△219	△370	△9.34
Difference (B-A)	△523	0	132	0	—
Percentage Change (%)	△7.5	0.0	37.6	0.0	—
[Reference] Prior Year Results (FY 2022)	10,008	1,963	1,999	1,179	30.20

2. Reasons for changes

Although the impact of generic bendamustine products were generally in line with our expectations, delays in treatment of malignant lymphoma continued due to COVID-19, despite the downgrading of the severity of COVID-19 status as an infectious disease. As a result, compared with the previously announced forecast, the forecast of net sales was revised downward by 523 million yen, to 6,477 million yen.

While we are prioritizing R&D investment for our ongoing global development of BCV, we have reviewed expenses and reduced selling, general and administrative expenses to reduce the impact of the decrease in sales, resulting in an operating loss of 331 million yen, an ordinary loss of 219 million yen (compared to 351 million yen in the previously announced forecast due to foreign exchange gains

on foreign currency denominated assets). Forecasted net loss attributable to owners of the parent remains 331 million yen, which is unchanged from the previously announced forecast, with the impact of foreign exchange gains set off by an increase in deferred income taxes.

*Earnings forecasts, financial projections, and other forecasts or forward looking statements contained in this disclosure have been prepared by the Company at its discretion and based on information available to the Company as of the date of this disclosure. Actual results may vary materially from the information contained in this disclosure as a result of changes to business, economic, financial, or other assumptions and conditions.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125